English
简体中文
Total: £ 56.28
Published Date: 2026-03-24 | Pages: 97 | Tables: 99 | Pharma & Healthcare
The global Meningococcal Group A and C Conjugate Vaccine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Meningococcal Group A and C Conjugate Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for Meningococcal Group A and C Conjugate Vaccine is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Meningococcal Group A and C Conjugate Vaccine is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Meningococcal Group A and C Conjugate Vaccine include Sanofi Pasteur, GSK, Pfizer, Chongqing Zhifei Biological Products, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Meningococcal Group A and C Conjugate Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Meningococcal Group A and C Conjugate Vaccine. The Meningococcal Group A and C Conjugate Vaccine market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Meningococcal Group A and C Conjugate Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Meningococcal Group A and C Conjugate Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Sanofi Pasteur
GSK
Pfizer
Chongqing Zhifei Biological Products
Segment by Type
Prefilled
Non-prefilled
by Application
Adults
Children
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Meningococcal Group A and C Conjugate Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Meningococcal Group A and C Conjugate Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Meningococcal Group A and C Conjugate Vaccine Market Overview
1.1 Product Definition
1.2 Meningococcal Group A and C Conjugate Vaccine by Type
1.2.1 Global Meningococcal Group A and C Conjugate Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Prefilled
1.2.3 Non-prefilled
1.3 Meningococcal Group A and C Conjugate Vaccine by Application
1.3.1 Global Meningococcal Group A and C Conjugate Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Adults
1.3.3 Children
1.4 Global Meningococcal Group A and C Conjugate Vaccine Market Size Estimates and Forecasts
1.4.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue 2021–2032
1.4.2 Global Meningococcal Group A and C Conjugate Vaccine Sales 2021–2032
1.4.3 Global Meningococcal Group A and C Conjugate Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Meningococcal Group A and C Conjugate Vaccine Market Competition by Manufacturers
2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Meningococcal Group A and C Conjugate Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Meningococcal Group A and C Conjugate Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Date of Entry into the Industry
2.8 Global Meningococcal Group A and C Conjugate Vaccine Market Competitive Situation and Trends
2.8.1 Global Meningococcal Group A and C Conjugate Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Meningococcal Group A and C Conjugate Vaccine Players Market Share by Revenue
2.8.3 Global Meningococcal Group A and C Conjugate Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Meningococcal Group A and C Conjugate Vaccine Market Scenario by Region
3.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021–2032
3.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021–2026
3.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2027–2032
3.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2021–2032
3.3.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2021–2026
3.3.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2027–2032
3.4 North America Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.4.1 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.4.3 North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.5.1 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.5.3 Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.7.1 Latin America Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021–2032)
4.1.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021–2026)
4.1.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027–2032)
4.1.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021–2032)
4.2.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021–2026)
4.2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027–2032)
4.2.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Meningococcal Group A and C Conjugate Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021–2032)
5.1.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021–2026)
5.1.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027–2032)
5.1.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021–2032)
5.2.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021–2026)
5.2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027–2032)
5.2.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Meningococcal Group A and C Conjugate Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Sanofi Pasteur
6.1.1 Sanofi Pasteur Company Information
6.1.2 Sanofi Pasteur Description and Business Overview
6.1.3 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.1.5 Sanofi Pasteur Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Chongqing Zhifei Biological Products
6.4.1 Chongqing Zhifei Biological Products Company Information
6.4.2 Chongqing Zhifei Biological Products Description and Business Overview
6.4.3 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolio
6.4.5 Chongqing Zhifei Biological Products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meningococcal Group A and C Conjugate Vaccine Industry Chain Analysis
7.2 Meningococcal Group A and C Conjugate Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meningococcal Group A and C Conjugate Vaccine Production Mode & Process Analysis
7.4 Meningococcal Group A and C Conjugate Vaccine Sales and Marketing
7.4.1 Meningococcal Group A and C Conjugate Vaccine Sales Channels
7.4.2 Meningococcal Group A and C Conjugate Vaccine Distributors
7.5 Meningococcal Group A and C Conjugate Vaccine Customer Analysis
8 Meningococcal Group A and C Conjugate Vaccine Market Dynamics
8.1 Meningococcal Group A and C Conjugate Vaccine Industry Trends
8.2 Meningococcal Group A and C Conjugate Vaccine Market Drivers
8.3 Meningococcal Group A and C Conjugate Vaccine Market Challenges
8.4 Meningococcal Group A and C Conjugate Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Meningococcal Group A and C Conjugate Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Meningococcal Group A and C Conjugate Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Meningococcal Group A and C Conjugate Vaccine Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Meningococcal Group A and C Conjugate Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Meningococcal Group A and C Conjugate Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Meningococcal Group A and C Conjugate Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Meningococcal Group A and C Conjugate Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Meningococcal Group A and C Conjugate Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2021–2026
Table 18. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2027–2032
Table 20. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
Table 27. North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
Table 28. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
Table 32. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
Table 33. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
Table 42. Latin America Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
Table 43. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Type (2021–2026)
Table 51. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Type (2027–2032)
Table 52. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Type (2021–2026)
Table 59. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Type (2027–2032)
Table 60. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Application (2021–2026)
Table 61. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units) by Application (2027–2032)
Table 62. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Application (2021–2026)
Table 69. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Application (2027–2032)
Table 70. Sanofi Pasteur Company Information
Table 71. Sanofi Pasteur Description and Business Overview
Table 72. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product
Table 74. Sanofi Pasteur Recent Developments/Updates
Table 75. GSK Company Information
Table 76. GSK Description and Business Overview
Table 77. GSK Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. GSK Meningococcal Group A and C Conjugate Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Pfizer Meningococcal Group A and C Conjugate Vaccine Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Chongqing Zhifei Biological Products Company Information
Table 86. Chongqing Zhifei Biological Products Description and Business Overview
Table 87. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product
Table 89. Chongqing Zhifei Biological Products Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Meningococcal Group A and C Conjugate Vaccine Distributors List
Table 93. Meningococcal Group A and C Conjugate Vaccine Customers List
Table 94. Meningococcal Group A and C Conjugate Vaccine Market Trends
Table 95. Meningococcal Group A and C Conjugate Vaccine Market Drivers
Table 96. Meningococcal Group A and C Conjugate Vaccine Market Challenges
Table 97. Meningococcal Group A and C Conjugate Vaccine Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of Meningococcal Group A and C Conjugate Vaccine
Figure 2. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Meningococcal Group A and C Conjugate Vaccine Market Share by Type: 2025 & 2032
Figure 4. Prefilled Product Picture
Figure 5. Non-prefilled Product Picture
Figure 6. Global Meningococcal Group A and C Conjugate Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Meningococcal Group A and C Conjugate Vaccine Market Share by Application: 2025 & 2032
Figure 8. Adults
Figure 9. Children
Figure 10. Global Meningococcal Group A and C Conjugate Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global Meningococcal Group A and C Conjugate Vaccine Market Size (US$ Million), 2021–2032
Figure 12. Global Meningococcal Group A and C Conjugate Vaccine Sales (K Units), 2021–2032
Figure 13. Global Meningococcal Group A and C Conjugate Vaccine Average Price (US$/Unit), 2021–2032
Figure 14. Meningococcal Group A and C Conjugate Vaccine Report Years Considered
Figure 15. Meningococcal Group A and C Conjugate Vaccine Sales Share by Manufacturers in 2025
Figure 16. Global Meningococcal Group A and C Conjugate Vaccine Revenue Share by Manufacturers in 2025
Figure 17. Top 5 and Top 10 Global Meningococcal Group A and C Conjugate Vaccine Players: Market Share by Revenue in Meningococcal Group A and C Conjugate Vaccine in 2025
Figure 18. Meningococcal Group A and C Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 19. Global Meningococcal Group A and C Conjugate Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 20. North America Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
Figure 21. North America Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
Figure 22. United States Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 23. Canada Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Europe Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
Figure 25. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
Figure 26. Germany Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. France Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. U.K. Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Italy Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Russia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021–2032)
Figure 32. Asia Pacific Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021–2032)
Figure 33. China Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Japan Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. South Korea Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. India Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Australia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. China Taiwan Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Latin America Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
Figure 41. Latin America Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
Figure 42. Mexico Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Brazil Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Argentina Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Colombia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Country (2021–2032)
Figure 47. Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Country (2021–2032)
Figure 48. Turkey Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. UAE Meningococcal Group A and C Conjugate Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Global Sales Market Share of Meningococcal Group A and C Conjugate Vaccine by Type (2021–2032)
Figure 52. Global Revenue Market Share of Meningococcal Group A and C Conjugate Vaccine by Type (2021–2032)
Figure 53. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Type (2021–2032)
Figure 54. Global Sales Market Share of Meningococcal Group A and C Conjugate Vaccine by Application (2021–2032)
Figure 55. Global Revenue Market Share of Meningococcal Group A and C Conjugate Vaccine by Application (2021–2032)
Figure 56. Global Meningococcal Group A and C Conjugate Vaccine Price (US$/Unit) by Application (2021–2032)
Figure 57. Meningococcal Group A and C Conjugate Vaccine Value Chain
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
